Phibro Animal Health (NASDAQ:PAHC) Cut to “Hold” at Zacks Research

Zacks Research cut shares of Phibro Animal Health (NASDAQ:PAHC) from a strong-buy rating to a hold rating in a research report sent to investors on Monday,Zacks.com reports.

A number of other equities analysts have also weighed in on the company. JPMorgan Chase & Co. upped their target price on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Weiss Ratings upgraded shares of Phibro Animal Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, November 5th. Morgan Stanley set a $34.00 price objective on shares of Phibro Animal Health in a research note on Thursday, August 28th. Finally, Bank of America lifted their price objective on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an “underperform” rating in a report on Friday, August 29th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $31.40.

Phibro Animal Health Price Performance

PAHC stock opened at $45.32 on Monday. The company has a debt-to-equity ratio of 2.46, a current ratio of 2.76 and a quick ratio of 1.25. The company’s 50-day moving average is $40.20 and its 200-day moving average is $31.53. The stock has a market capitalization of $1.84 billion, a PE ratio of 38.41, a price-to-earnings-growth ratio of 1.24 and a beta of 0.81. Phibro Animal Health has a 1 year low of $16.16 and a 1 year high of $46.42.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. The business had revenue of $363.89 million for the quarter, compared to the consensus estimate of $345.44 million. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Equities research analysts expect that Phibro Animal Health will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 17th. Investors of record on Wednesday, November 26th will be given a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, November 26th. Phibro Animal Health’s dividend payout ratio (DPR) is presently 28.92%.

Insiders Place Their Bets

In other Phibro Animal Health news, CEO Jack Bendheim sold 38,303 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $45.29, for a total value of $1,734,742.87. Following the completion of the sale, the chief executive officer directly owned 20,577 shares of the company’s stock, valued at approximately $931,932.33. This represents a 65.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 109,159 shares of company stock worth $4,620,198 in the last 90 days. 50.13% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Phibro Animal Health

A number of hedge funds and other institutional investors have recently modified their holdings of PAHC. LPL Financial LLC boosted its position in Phibro Animal Health by 46.8% in the first quarter. LPL Financial LLC now owns 128,335 shares of the company’s stock worth $2,741,000 after purchasing an additional 40,889 shares during the last quarter. Kings Path Partners LLC increased its position in shares of Phibro Animal Health by 87.3% during the 2nd quarter. Kings Path Partners LLC now owns 20,600 shares of the company’s stock valued at $526,000 after purchasing an additional 9,600 shares during the last quarter. Voya Investment Management LLC raised its stake in shares of Phibro Animal Health by 44.3% during the 1st quarter. Voya Investment Management LLC now owns 31,894 shares of the company’s stock worth $681,000 after purchasing an additional 9,796 shares during the period. Trexquant Investment LP bought a new stake in shares of Phibro Animal Health during the 1st quarter worth $385,000. Finally, Principal Financial Group Inc. boosted its holdings in shares of Phibro Animal Health by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 101,356 shares of the company’s stock worth $2,165,000 after buying an additional 2,573 shares during the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.